Department of Oncology, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Department of Oncology, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Semin Cancer Biol. 2021 Dec;77:67-82. doi: 10.1016/j.semcancer.2021.02.008. Epub 2021 Feb 16.
Epithelial ovarian carcinoma (EOC) encompasses distinct histological, molecular and genomic entities that determine intrinsic sensitivity to platinum-based chemotherapy. Current management of each subtype is determined by factors including tumour grade and stage, but only a small number of biomarkers can predict treatment response. The recent incorporation of PARP inhibitors into routine clinical practice has underscored the need to personalise ovarian cancer treatment based on tumour biology. In this article, we review the strengths and limitations of predictive biomarkers in current clinical practice and highlight integrative strategies that may inform the development of future personalised medicine programs and composite biomarkers.
上皮性卵巢癌 (EOC) 包含不同的组织学、分子和基因组实体，这些实体决定了对铂类化疗的内在敏感性。目前对每种亚型的治疗管理取决于肿瘤分级和分期等因素，但只有少数生物标志物可以预测治疗反应。最近 PARP 抑制剂纳入常规临床实践突显了根据肿瘤生物学为卵巢癌治疗进行个体化的必要性。在本文中，我们回顾了当前临床实践中预测性生物标志物的优缺点，并强调了可能为未来个体化医学计划和综合生物标志物的开发提供信息的综合策略。
